Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Current treatments like R-CHOP have limitations, necessitating improved therapeutic strategies.
• Genetic subtyping and understanding the tumor microenvironment are crucial for personalized medicine in DLBCL.

Purpose of the Study:

• To evaluate the efficacy and safety of R-CHOP combined with targeted agents (R-CHOP-X) versus R-CHOP alone in newly diagnosed intermediate- or high-risk DLBCL.
• To assess the role of genetic subtyping in guiding therapy selection.
• To validate a simplified genetic subtyping algorithm and lymphoma microenvironment subtypes.

Main Methods:

• GUIDANCE-01, a randomized, phase II clinical trial (NCT04025593).
• 128 patients with newly diagnosed DLBCL were randomized 1:1 to receive R-CHOP-X or R-CHOP.
• Post hoc RNA-sequencing was used to validate genetic and microenvironment subtypes.

Main Results:

• R-CHOP-X demonstrated a significantly higher complete response rate (88% vs. 66%, p=0.003) and overall response rate (92% vs. 73%, p=0.005) compared to R-CHOP.
• Two-year progression-free survival was significantly improved with R-CHOP-X (88% vs. 63%, p<0.001).
• Two-year overall survival rates were also higher in the R-CHOP-X arm (94% vs. 77%, p=0.001).

Conclusions:

• R-CHOP-X is an effective and safe mechanism-based tailored therapy for newly diagnosed DLBCL.
• Targeting both genetic and microenvironmental alterations improves patient outcomes.
• The simplified genetic subtyping algorithm is validated and useful for guiding DLBCL treatment.